ALK-Abello new product for house dust mite allergic rhinitis in Japan

26 November 2015

Danish allergy specialist ALK-Abello on Thursday said its sublingual allergy immunotherapy product Miticure to treat house dust mite allergic rhinitis, will now be available for prescription in Japan.

The company said the product has been placed on the Japanese National Health Insurance reimbursement list and will be launched in the beginning of December 2015.

Miticure is the Japanese trade name of the sublingual allergy immunotherapy tablet licensed by ALK to Torii Pharmaceutical (TYO:4551) for Japan. The product is currently available for treatment for adults. Torii is currently conducting a Phase III clinical trial for the product for approval for pediatric use (5-11 years).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK